Skip to main content
Premium Trial:

Request an Annual Quote

23andMe, Reset Therapeutics Partner to Study Circadian Clock Genes

NEW YORK (GenomeWeb) – 23andMe today announced an agreement with drug developer Reset Therapeutics to study the genetics of the circadian clock.

The goal of the collaboration is to develop drug targets for therapeutics that will restore the body's 24-hour physiological rhythms, Reset said in a statement.

Through this collaboration, 23andMe will provide Reset scientists with de-identified, aggregated data from more than 650,000 customers who have consented for their genomic information to be a part of scientific research.

"Working with 23andMe, we will amplify our R&D capabilities by incorporating a large-scale human genetics element in our research platform in a way that wasn't possible," Reset President and CEO Ross Bersot said in a statement. "With this collaboration we will be able to more efficiently and effectively drive our clinical programs."

The Reset research team will study the clock genes associated with chronotype, sleep, insulin resistance, stress response, and related pathophysiology to identify novel circadian drug targets.

Financial details of the agreement were not disclosed. 

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.